EXOZYMES INC.(EXOZ)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

EXOZYMES INC. (EXOZ) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. EXOZ is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.1m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q1 2026), EXOZYMES INC. reports net income of $-2.4M, free cash flow of $-1.6M. Top institutional holders of EXOZ by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Davidson Kahn Capital Management, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. EXOZ trades on the Nasdaq exchange and files with the SEC under CIK 2010788. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EXOZ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EXOZYMES INC. directly from SEC EDGAR.